Clinical trials recruiting for Triple Negative Breast Neoplasms
12
Recruiting trials
40
US states with sites
43
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Pembrolizumab | 6 |
| Carboplatin | 4 |
| Paclitaxel | 3 |
| Olaparib | 2 |
| Rescue Medication | 2 |
| Sacituzumab tirumotecan | 2 |
| Abemaciclib | 1 |
| BMS-936558-01 | 1 |
| BMS-986340 | 1 |
| Bevacizumab | 1 |
| Bicalutamide | 1 |
| Capecitabine | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 6 |
| Texas | 6 |
| New Jersey | 5 |
| Utah | 5 |
| New York | 4 |
| Tennessee | 4 |
| Virginia | 4 |
| Arizona | 3 |
| Florida | 3 |
| Georgia | 3 |
| Michigan | 3 |
| Ohio | 3 |
Top cities
Houston, Texas 5Dallas, Texas 4Hackensack, New Jersey 4Nashville, Tennessee 4New York, New York 4Los Angeles, California 3San Antonio, Texas 3Altamonte Springs, Florida 2Baltimore, Maryland 2Boston, Massachusetts 2
Self-screener
Recruiting trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
- Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
Related conditions
Trials recruiting for Triple Negative Breast Neoplasms often also study these conditions. Each links to its own recruiting-trial list.
Breast cancer 2239Pancreatic cancer 870Ovarian Neoplasms 18Lung cancer 2180Triple-negative breast cancer 138Non-small cell lung cancer 507Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 11Pancreatic Adenocarcinoma 49Gastric cancer 91
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Triple Negative Breast Neoplasms trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.